Overview

• Alliance Medical’s retrospective case-series identified several atypical FDG uptake patterns in patients taking GLP-1 agonists that can resemble malignancy or inflammation.
• Misinterpretation could prompt unnecessary investigations, incorrect cancer staging, and delays in treatment, the authors cautioned.
• The team does not recommend stopping GLP-1 therapy before PET-CT and advises imaging services to record patients’ current medicines to aid interpretation.
• Researchers plan to expand data collection across more imaging centers and establish international collaborations to support future guidelines.
• Usage of GLP-1s has surged, UK guidance on this imaging issue is absent, and Australian recommendations currently advise continuing treatment with fasting and glucose control.